Acute Disseminated Encephalomyelitis (ADEM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032
Acute disseminated encephalomyelitis (ADEM) is a rare neurological disorder that affects children more than adults. However, it could affect any age group of the population but can affect anyone. It is characterised by a brief but widespread attack of fibreslammation in the brain and spinal cord that damages myelin, the protective covering of nerve fibres. Symptoms of ADEM rapidly begin with encephalitis symptoms such as fever, nausea, headache, fatigue and vomiting, and in the most serious cases, seizures and coma. ADEM typically causes white matter damage, resulting in neurological symptoms such as visual loss in one or both eyes, weakness, even paralysis, and difficulty coordinating voluntary muscle movements. ADEM is sometimes misdiagnosed as a severe first attack of multiple sclerosis (MS) because the symptoms and appearance of the white matter injury on brain imaging are similar. However, ADEM has several characteristics that set it apart from MS.
- The incidence of Acute disseminated encephalomyelitis (ADEM) ranges from 1 to 2 cases in 250,000 population in the USA.
Thelansis’s “Acute Disseminated Encephalomyelitis (ADEM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Disseminated Encephalomyelitis (ADEM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Acute Disseminated Encephalomyelitis (ADEM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Acute Disseminated Encephalomyelitis (ADEM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
